期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肠促胰岛素类药物治疗糖尿病的安全性评价

The safety evaluation on incretinrelated agents in type 2 diabetes
下载PDF
导出
摘要 肠促胰岛素类药物主要有两种,一是GLP-1类似物,二是DPP-4抑制剂。前者通过外源性补充提高体内GLP-1水平、后者可延长内源性GLP-1活性而发挥保护胰岛β细胞功能、促进胰岛素合成和分泌、抑制β细胞凋亡、抑制胰高血糖素等作用而控制血糖,具有较好的临床应用前景。作为一类作用机制独特的新药,这类药物临床应用时间较短,其安全性问题受到广泛关注。本文对其作用特点和安全性进行评价,以期为2型糖尿病患者的临床用药提供参考。
作者 刘丽萍
机构地区 解放军第
出处 《药品评价》 CAS 2013年第23期33-37,46,共6页 Drug Evaluation
关键词 糖尿病 肠促胰岛素 GLP-1 GIP DPP-4
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献25

  • 1Aroda VR,Henry RR,Han J. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors:meta-analysis and systematic review[J].Clinical Therapeutics,2012,(06):1247-1258.
  • 2赵敏,杨丽,翟所迪.新作用靶点的抗糖尿病药物临床研究进展[J].中国新药杂志,2010,19(3):199-202. 被引量：13
  • 3Panchapakesan U,Mather A,Pol ock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease[J].Clinical Science,2013.124,17-26.
  • 4Tong J,Prigeon RL,Davis HW. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans[J].Diabetes,2010,(09):2145-2151.
  • 5Kielgast U,Asmar M,Madsbad S. Effect of glucagon-like peptide-1 on alpha-and beta-cell function in C-peptide-negative type 1 diabetic patients[J].Journal of Clinical Endocrinology and Metabolism,2010,(05):2492-2496.
  • 6Bertilsson G,Patrone C,Zachrisson O. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease[J].Journal of Neuroscience Research,2008,(02):326-338.
  • 7Hocher B,Reichetzeder C,Alter ML. Renal and cardiac effects of DPP-4 inhibitors-from preclinical development to clinical research[J].Kidney and Blood Pressure Research,2012,(01):65-84.
  • 8Bohannon N. Overview of the gliptin class(dipeptidyl peptidase-4 inhibitors)in clinical practice[J].Postgraduate Medicine,2009,(01):40-45.
  • 9Aroda VR,Henry RR,Han J. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors:meta-analysis and systematic review[J].Clinical Therapeutics,2012,(06):1247-1258.
  • 10Nauck M,Frid A,Hermansen K. Efficacy and safety comparison of liraglutide,glimepiride,and placebo,al in combination with metformin,in type 2 diabetes:the LEAD(liraglutide effect and action in diabetes)-2 study[J].Diabetes Care,2009,(01):84-90.doi:10.2337/dc08-1355.

二级参考文献17

  • 1WILD S, ROGLIC G, GREEN A, et al. Global prevalence of diabetes:estimates for the year2000 and projections for 2030 [J]. Diabetes Care, 2004,27 ( 10 ) : 1047 - 1053.
  • 2BUSE JB, KLONOFF DC, NIELSEN LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic bin-markers in patients with type 2 diabetes: an interim analysis of data from the open-label uncontrolled extension of three double-blind, placebo-controlled trials [J]. Clin Ther, 2007,29 (1): 139-153.
  • 3KIM D, MACCONELL L, ZHUANG D, et al. Effects of onceweekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjeets with type 2 diabetes [ J ]. Diabetes Care, 2007,30 ( 6 ) : 1487 - 1493.
  • 4VINEET SH, REED JR, BERGMAN A J, et al. Metabolism and excretion of the DPP- inhibilor [ 14C ] sitigliptin in humans[ J]. Drug Metab Dispos,2007 ,35 ( 4 ) :533 -538.
  • 5ASCHNER P, KIPNES MS, LUNCEFORD JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glyeemic control in patients with type 2 diabetes [J]. Diabetes Care,2006,29 (12) :2632 - 2637.
  • 6BERNARD C, AVRAHAM K, Ji Liu, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [ J ] . Diabetes Care, 2006,29 (12) :2638 -2643.
  • 7FDA Approves JANUMET^TM- DPP-4 inhibitor and metformin in a single tablet [EB/OL] http://www, diabetesincontrol, com/resuits, php? storyartiele =4881,2007 -06 - 12/2009 -05 - 16.
  • 8PRETLEY RE, JAUFFRET KS, GALLBREATH E, et al. Twelveweek monotherapy with the DPP-4 inbibitor vildagliptin improves glycemic control in subjects with type 2 diabetes [J]. Horm Metab Res, 2006,38(6) : 423 -428.
  • 9LIST JF, WOO V, MORALES E. et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes[J]. Diabetes Care ,2009,32(4) :650 - 657.
  • 10JABBOUR SA, GOLDSTEIN BJ. Sodium glucose co-transporter 2 inhibitors : blocking renal tuber reabsorption of glucose to improve glyceamic control in patientd with diabetes [J]. Int J Clin Proct,2008,62(8) :1279 - 1284.

共引文献12

药品评价
2013年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部